AstraZeneca prices $2bn three-tranche bond deal

AstraZeneca PLC has priced a $2bn global bond offering through its wholly owned subsidiary AstraZeneca Finance LLC.

Rhea-AI Filing Summary

AstraZeneca PLC has priced a $2bn global bond offering through its wholly owned subsidiary AstraZeneca Finance LLC. The bonds are issued in three fixed-rate tranches registered with the U.S. SEC and are fully and unconditionally guaranteed by AstraZeneca.

The tranches comprise $0.65bn of notes with a 4.000% coupon maturing on 2 March 2031, $0.60bn with a 4.300% coupon maturing on 2 March 2033, and $0.75bn with a 4.600% coupon maturing on 2 March 2036.

AstraZeneca expects to use the net proceeds for general corporate purposes, which may include refinancing existing debt. The company states that this bond issuance does not impact its financial guidance for 2026.

Insights

Corporate finance analyst

AstraZeneca raises $2bn in long-term debt without changing 2026 guidance.

AstraZeneca is adding $2bn of fixed-rate debt across three maturities from 2031 to 2036. Fixed coupons of 4.000%, 4.300%, and 4.600% lock in borrowing costs and extend the company’s debt maturity profile via a global SEC-registered transaction.

The company plans to use net proceeds for general corporate purposes, explicitly including possible refinancing of existing indebtedness. This points to balance-sheet management rather than funding a specific acquisition or major project, and it spreads obligations over multiple future dates.

Management explicitly notes that the bond issuance does not affect financial guidance for 2026. That statement anchors expectations that near-term earnings and cash flow targets remain unchanged, so the development is best viewed as a routine funding action rather than a thesis-changing event.

FAQ

What type of financing did AstraZeneca (AZN) announce in this Form 6-K?

AstraZeneca announced a global bond offering totaling $2bn through AstraZeneca Finance LLC. The notes are SEC-registered, issued in three fixed-rate tranches, and fully and unconditionally guaranteed by AstraZeneca, providing long-term financing for general corporate purposes and potential debt refinancing.

How large is AstraZeneca’s new bond offering and how is it structured?

The bond offering totals $2bn and is split into three tranches. These include $0.65bn maturing in 2031, $0.60bn maturing in 2033, and $0.75bn maturing in 2036, each carrying a fixed interest coupon and issued under an effective Form F-3 shelf registration.

What are the interest rates and maturities on AstraZeneca’s new notes?

AstraZeneca’s notes carry fixed coupons of 4.000% due March 2, 2031, 4.300% due March 2, 2033, and 4.600% due March 2, 2036. This staggered maturity schedule spreads refinancing risk over time at clearly defined interest costs for the company.

What will AstraZeneca (AZN) use the $2bn bond proceeds for?

AstraZeneca expects to use the net proceeds for general corporate purposes. This may include refinancing existing indebtedness, giving the company flexibility to manage its capital structure, address upcoming debt maturities, or support ongoing operations as needed over time.

Does AstraZeneca’s $2bn bond issuance affect its 2026 financial guidance?

The company states the bond issuance does not impact its 2026 financial guidance. This indicates management believes planned earnings and financial targets for that year remain achievable despite the additional long-term borrowing described in this offering.

Who managed AstraZeneca’s new bond offering and under what registration?

BofA Securities, Deutsche Bank Securities, HSBC Securities (USA), and Mizuho Securities USA acted as joint book-running managers. The notes are issued under AstraZeneca’s effective shelf registration statement on Form F-3 filed with the SEC, using an accompanying prospectus and supplement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 08:59 AM Learn about SEC filing dates

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of February 2026

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X      Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __     No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

AstraZeneca prices a $2bn bond offering

26 February 2026

AstraZeneca prices a $2bn bond offering

AstraZeneca PLC ("AstraZeneca") announces that its wholly owned subsidiary AstraZeneca Finance LLC, priced a three tranche global bond offering totalling $2bn on 25 February 2026. The offering is expected to close on 2 March 2026, subject to customary closing conditions. The transaction, which is a global offering registered with the U.S. Securities and Exchange Commission ("SEC"), consists of the following three tranches:

Notes issued by AstraZeneca Finance LLC and fully and unconditionally guaranteed by AstraZeneca

●      $0.65bn of fixed rate notes with a coupon of 4.000%, maturing 2 March 2031;

●      $0.60bn of fixed rate notes with a coupon of 4.300%, maturing 2 March 2033; and

●      $0.75bn of fixed rate notes with a coupon of 4.600%, maturing 2 March 2036.

AstraZeneca expects to use the net proceeds of the offering for general corporate purposes, which may include the refinancing of existing indebtedness.

BofA Securities, Inc., Deutsche Bank Securities Inc., HSBC Securities (USA) Inc. and Mizuho Securities USA LLC acted as joint book-running managers on the transaction.

The notes will be issued under AstraZeneca's effective shelf registration statement on Form F-3, which AstraZeneca and AstraZeneca Finance LLC filed with the SEC on 19 March 2024. The offering is being made solely by means of the prospectus contained within that shelf registration statement, along with a prospectus supplement forming part of the effective registration statement, which investors should read.

A copy of the prospectus supplement and accompanying prospectus relating to the offering can be obtained by contacting BofA Securities, Inc. by telephone at +1-800-294-1322; Deutsche Bank Securities Inc. toll-free at +1-800-503-4611; HSBC Securities (USA) Inc., by telephone at +1-866-811-8049; or Mizuho Securities USA LLC, by telephone at +1 866-271-7403. Readers may also download these documents for free by visiting the Electronic Data Gathering, Analysis, and Retrieval (EDGAR) system on the SEC website at www.sec.gov. 

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

The bond issuance does not impact AstraZeneca's financial guidance for 2026. 

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 26 February 2026

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary